Moreover, the 36-month beta value for AIM is -0.29. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AIM is 56.25M and currently, short sellers hold a 0.92% of that float. On January 22, 2025, AIM’s average trading volume was 568.27K shares.
AIM) stock’s latest price update
The stock price of AIM ImmunoTech Inc (AMEX: AIM) has surged by 7.62 when compared to previous closing price of 0.22, but the company has seen a 22.98% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-22 that Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS
AIM’s Market Performance
AIM ImmunoTech Inc (AIM) has seen a 22.98% rise in stock performance for the week, with a 20.41% gain in the past month and a -5.75% plunge in the past quarter. The volatility ratio for the week is 7.77%, and the volatility levels for the past 30 days are at 9.64% for AIM. The simple moving average for the last 20 days is 12.17% for AIM stock, with a simple moving average of -26.16% for the last 200 days.
AIM Trading at 9.81% from the 50-Day Moving Average
After a stumble in the market that brought AIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.94% of loss for the given period.
Volatility was left at 9.64%, however, over the last 30 days, the volatility rate increased by 7.77%, as shares surge +24.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.92% lower at present.
During the last 5 trading sessions, AIM rose by +23.76%, which changed the moving average for the period of 200-days by -55.17% in comparison to the 20-day moving average, which settled at $0.2105. In addition, AIM ImmunoTech Inc saw 19.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AIM starting from Equels Thomas K, who purchase 20,000 shares at the price of $0.21 back on Nov 21 ’24. After this action, Equels Thomas K now owns 1,657,968 shares of AIM ImmunoTech Inc, valued at $4,240 using the latest closing price.
MITCHELL WILLIAM M, the Director of AIM ImmunoTech Inc, sale 4,580 shares at $0.19 during a trade that took place back on Dec 19 ’24, which means that MITCHELL WILLIAM M is holding 118,549 shares at $884 based on the most recent closing price.
Stock Fundamentals for AIM
Current profitability levels for the company are sitting at:
- -146.88 for the present operating margin
- 0.2 for the gross margin
The net margin for AIM ImmunoTech Inc stands at -125.94. The total capital return value is set at -8.0. Equity return is now at value -187.58, with -115.46 for asset returns.
Based on AIM ImmunoTech Inc (AIM), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -6.08. The debt to equity ratio resting at 1.17. The interest coverage ratio of the stock is -25.67.
Currently, EBITDA for the company is -31.68 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 91.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
To wrap up, the performance of AIM ImmunoTech Inc (AIM) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
